1. Background
2. Objectives
3. Patients and Methods
3.1. Study Area
3.2. Samples Processing and Antibiogram
3.3. Bacterial Isolates and Confirmation
4. Results
4.1. Infection Evaluation
| Bacterial Isolates | Specimen Sources | Total, No. (%) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wound Swab | Urine | Blood Culture | Suction Tip | Catheter Tip | Purulent Discharge | Bronchial Wash | Peritoneal Fluid | Ear Swab | Pleural Fluid | Sputum | ||
| Gram-positive | ||||||||||||
| S. aureus | 36 | ND | 20 | 12 | ND | ND | ND | ND | ND | ND | ND | 68 (22.7) |
| Gram-negative | ||||||||||||
| E. coli | 39 | 61 | 7 | 4 | 1 | 1 | ND | 1 | ND | 1 | ND | 115 (38.3) |
| K. pneumonia | 17 | 18 | 20 | 4 | 3 | 1 | ND | ND | 1 | ND | 1 | 65 (21.7) |
| P. aeruginosa | 24 | 18 | 7 | ND | 2 | ND | 1 | ND | ND | ND | ND | 52 (17.3) |
| Total, No. (%) | 116 (39) | 97 (32.3) | 54 (17.8) | 20 (6.7) | 6 (2) | 2 (0.8) | 1 (0.3) | 1 (0.3) | 1 (0.3) | 1 (0.3) | 1 (0.3) | 300 (100) |
4.2. Antibiotic Susceptibility Testing
| Antibiotic | Gram-Positive Bacteria Isolates (S. aureus) (n = 68) | ||
|---|---|---|---|
| Resistant | Intermediate | Sensitive | |
| Amoxicillin/clavulanic | 38 (55.9) | 0 | 30 (44.1) |
| Ampicillin | 64 (94.1) | 4 (5.9) | 0 |
| Azithromycin | 34 (50.0) | 4 (5.9) | 30 (44.1) |
| Ciprofloxacin | 30 (44.1) | 0 | 38 (55.9) |
| Clindamycin | 20 (29.4) | 0 | 48 (70.6) |
| Daptomycin | 0 | 7 (10.3) | 61 (89.7) |
| Erythromycin | 30 (44.1) | 8 (11.8) | 30 (44.1) |
| Fosfomycin | 13 (19.1) | 0 | 55 (80.9) |
| Fusidic Acid | 4 (5.9) | 26 (38.2) | 38 (55.9) |
| Gentamicin | 12 (17.6) | 0 | 56 (82.4) |
| Imipenem | 43 (63.2) | 0 | 25 (36.8) |
| Levofloxacin | 17 (25.0) | 0 | 51 (75.0) |
| Linezolid | 64 (94.1) | 4 (5.9) | 0 |
| Moxifloxacin | 18(26.5) | 4 (5.9) | 46 (67.6) |
| Mupirocin | 13 (19.1) | 0 | 55 (80.9) |
| Oxacillin | 38 (55.9) | 0 | 30 (44.1) |
| Penicillin | 4 (5.9) | 0 | 64 (94.1) |
| Rifampin | 8 (11.8) | 0 | 60 (88.2) |
| Synercid | 4 (5.9) | 0 | 64 (94.1) |
| Teicoplanin | 4 (5.9) | 0 | 64 (94.1) |
| Tetracycline | 25 (36.8) | 0 | 43 (63.2) |
| Trimethoprim/sulfa | 8 (11.8) | 0 | 60 (88.2) |
| Vancomycin | 4 (5.9) | 0 | 64 (94.1) |
| Gram-Negative Bacterial Isolates (n = 232) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Antibiotic | E. coli (n = 115) | K. pneumonia (n = 65) | P. aeruginosa (n = 52) | ||||||
| Resistant | Intermediate | Sensitive | Resistant | Intermediate | Sensitive | Resistant | Intermediate | Sensitive | |
| Amikacin | 90 (78.26) | 0 | 25 (21.73) | 15 (23.07) | 0 | 50 (76.92) | 26 (50) | 0 | 26 (50) |
| Amox-Clav | 35 (30.43) | 20 (17.39) | 60 (52.17) | 35 (53.84) | 10 (15.38) | 20 (30.76) | 32 (61.5) | 0 | 20 (24.4) |
| Ampicillin | 100 (86.95) | 0 | 15 (13.04) | 65 (100) | 0 | 0 | 32 (61.5) | 0 | 20 (24.4) |
| Cefazoline | 55 (47.82) | 0 | 60 (52.17) | 50 (76.92) | 0 | 15 (23.07) | 52 (100) | 0 | 0 |
| Cefepime | 50 (43.47) | 0 | 65 (56.52) | 50 (76.92) | 0 | 15 (23.07) | 32 (61.5) | 0 | 20 (24.4) |
| Cefotaxime | 50 (43.47) | 0 | 65 (56.52) | NT | NT | NT | 45 (86.5) | 0 | 7 (13.5) |
| Cefoxitin | 40 (34.78) | 0 | 75 (65.21) | 30 (46.15) | 0 | 35 (53.84) | 52 (100) | 0 | 0 |
| Cefuroxime | 50 (43.47) | 5 (4.34) | 60 (52.17) | 50 (76.92) | 0 | 15 (23.07) | 45 (86.5) | 0 | 7 (13.5) |
| Ciprofloxacin | 70 (60.86) | 5 (4.34) | 40 (34.78) | 40 (61.53) | 5 (7.69) | 20 (30.76) | 39 (75) | 0 | 13 (25) |
| Ertapenem | 20 (17.39) | 0 | 95 (82.6) | 15 (23.07) | 15 (23.07) | 35 (53.84) | 34 (65.5) | 12 (25) | 6 (12.5) |
| Fosfomycin | 10 (8.69) | 0 | 105 (91.3) | 25 (38.46) | 0 | 40 (61.53) | 32 (61.5) | 0 | 20 (37.5) |
| Gentamicin | 55 (47.82) | 5 (4.34) | 55 (47.82) | 30 (46.15) | 0 | 35 (53.84) | 38 (75) | 0 | 14 (27) |
| Imipenem | 5 (4.34) | 5 (4.34) | 105 (91.3) | 10 (15.38) | 0 | 55 (84.61) | 19 (36.5) | 7 (13.5) | 26 (50) |
| Levofloxacin | 60 (52.17) | 0 | 55 (47.82) | 25 (38.46) | 5 (7.69) | 35 (53.84) | 39 (75) | 0 | 13 (25) |
| Mezlocillin | 90 (78.26) | 5 (4.34) | 20 (17.39) | 60 (92.3) | 0 | 5 (7.69) | 39 (75) | 0 | 13 (25) |
| Pip-Tazo | 15 (13.04) | 0 | 100 (86.95) | 15 (23.07) | 0 | 50 (76.92) | 20 (38.5) | 0 | 32 (61.5) |
| Piperacillin | 90 (78.26) | 0 | 25 (21.73) | 60 (92.3) | 0 | 5 (7.69) | NT | NT | NT |
| Tetracycline | 75 (65.21) | 0 | 40 (34.78) | 30 (46.15) | 5 (7.69) | 30 (46.15) | 52 (100) | 0 | 0 |
| Tigecycline | 15 (13.04) | 0 | 100 (86.95) | 15 (23.07) | 5 (7.69) | 45 (69.23) | NT | NT | NT |
| Tobramycin | 65 (56.52) | 5 (4.34) | 45 (39.13) | 40 (61.53) | 0 | 25 (38.46) | 34 (65.4) | 6 (11.5) | 12 (23.1) |
| Trimeth/Sulfa | 75 (65.21) | 0 | 40 (34.78) | 40 (61.53) | 0 | 25 (38.46) | 52 (100) | 0 | 0 |
Abbreviations: Amox-Clav, Amoxicillin-clavulanic; Pip-Tazo, Piperacillin-Tazobactam; Trimeth-Sulfa, Trimethoprim-Sulfamethoxazole; NT, not tested.
aValues are expressed as No. (%).
4.3. Validation of Resistant Isolates
| Antibiotic-Resistant Organism | Ward | |||||||
|---|---|---|---|---|---|---|---|---|
| ICU | Female Surgical Ward | Male Surgical Ward | Obstetrics Ward | Pediatric Ward | Artificial kidney Unit | Nursery | Total | |
| Methicillin-resistant S. aureus | 8/8 (100) | 32/32 (100) | 16/16 (100) | ND | ND | 8/8 (100) | ND | 64/64 (100) |
| Ampicillin-resistant K. pneumonia | 16/16 (100) | 8/8 (100) | 19/20 (95.0) | 4/4 (100) | 3/4 (75.0) | ND | 6/8 (75.0) | 56/60 (93.3) |
| Amikacin-, Ampicillin-, Mezlocillin-, or Piperacillin-resistant E. coli | 11/17 (64.7) | 28/28 (100) | 20/29 (68.9) | 11/16 (68.7) | 6/9 (66.7) | 5/8 (62.5) | ND | 81/107 (75.70) |
| Cefazoline-, Cefoxitin-, Tetracycline-, or Trimeth/Sulfa-resistant P. aeruginosa | 20/20 (100) | 4/4 (100) | 20/20 (100) | ND | ND | 8/8 (100) | ND | 52/52 (100) |
| Total | 55/61 (90.2) | 72/72 (100) | 75/85 (88.2) | 15/20 (75.0) | 9/13 (69.2) | 13/24 (54.2%) | 6/8 (75.0) | 253/283 (89.4) |
Abbreviations: ICU, intensive care unit; ND, the microbe not detected in that area; Trimeth-Sulfa, Trimethoprim-Sulfamethoxazole.
aData are presented as No. of resistant isolates.
bTotal No. of isolates tested (%).